TY - JOUR
T1 - Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen
AU - Flexner, Charles
AU - Murphy, Brian R.
AU - Rooney, James F.
AU - Wohlenberg, Charles
AU - Yuferov, Vadim
AU - Notkins, Abner L.
AU - Moss, Bernard
PY - 1988
Y1 - 1988
N2 - A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.
AB - A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.
UR - http://www.scopus.com/inward/record.url?scp=0023689085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023689085&partnerID=8YFLogxK
U2 - 10.1038/335259a0
DO - 10.1038/335259a0
M3 - Article
C2 - 2842693
AN - SCOPUS:0023689085
SN - 0028-0836
VL - 335
SP - 259
EP - 262
JO - Nature
JF - Nature
IS - 6187
ER -